Trillium Therapeutics Inc. (NASDAQ:TRIL) Insider Sells $39,834.68 in Stock

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) insider Penka Petrova sold 2,708 shares of the firm’s stock in a transaction that occurred on Thursday, January 7th. The stock was sold at an average price of $14.71, for a total value of $39,834.68. Following the transaction, the insider now owns 2,708 shares in the company, valued at $39,834.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

TRIL opened at $14.51 on Thursday. The stock has a market cap of $1.46 billion, a PE ratio of -5.90 and a beta of 2.04. The business has a 50 day moving average of $14.58 and a 200-day moving average of $12.30. Trillium Therapeutics Inc. has a 52 week low of $2.26 and a 52 week high of $20.96.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Sunday, November 15th. The biotechnology company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.33). Sell-side analysts predict that Trillium Therapeutics Inc. will post -1.53 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can bought a new position in Trillium Therapeutics during the 2nd quarter valued at approximately $30,000. Advisor Group Holdings Inc. increased its holdings in shares of Trillium Therapeutics by 42.9% in the 2nd quarter. Advisor Group Holdings Inc. now owns 6,660 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,000 shares in the last quarter. Great West Life Assurance Co. Can bought a new stake in shares of Trillium Therapeutics in the 3rd quarter worth $66,000. Marshall Wace LLP bought a new stake in shares of Trillium Therapeutics in the first quarter worth $73,000. Finally, Laidlaw Wealth Management LLC bought a new stake in shares of Trillium Therapeutics in the second quarter worth $85,000. 66.60% of the stock is owned by institutional investors.

Several research firms have weighed in on TRIL. ValuEngine cut Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 1st. Craig Hallum increased their price objective on Trillium Therapeutics from $15.00 to $21.00 in a report on Wednesday, November 18th. Bloom Burton cut Trillium Therapeutics from a “buy” rating to an “accumulate” rating in a report on Tuesday, December 8th. HC Wainwright increased their price objective on Trillium Therapeutics from $16.50 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, November 18th. Finally, Evercore ISI began coverage on Trillium Therapeutics in a report on Monday, October 12th. They issued an “outperform” rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $17.85.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Article: Dual Listing What You Need to Know

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.